Internal Medicine, Hematology & Oncology · Los Angeles, CA
NPI
1679590566
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
1300 N Vermont Ave # 606
Los Angeles, CA, 90027
Phone (323) 660-6200
Groups this clinician bills Medicare through
Medicare paid, 2024
$476K
5,459 services
Medicare patients, 2024
228
Average age 74
Drug cost, 2024
$3.9M
1,453 prescriptions
Company payments, 2025
$117
From 9 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Ghassan Al-Jazayrly was code 99232 (hospital e&m - subsequent), 1,628 times for 159 patients. In total Ghassan Al-Jazayrly billed 5,459 services in 49 codes, and Medicare paid $476K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2007-07-09.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 1,628 | 159 | $58.48 | $95K |
| 99223 Hospital E&M - Initial | Facility | 215 | 175 | $129.04 | $28K |
| 96413 Chemotherapy Administration | Office | 182 | 26 | $111.81 | $20K |
| 96372 Injection Administration | Office | 148 | 35 | $11.20 | $1,658 |
| 96367 Intravenous Infusion, Hydration | Office | 119 | 16 | $25.30 | $3,011 |
| J0897 Injection, denosumab, 1 mg | Office | 75 | 23 | $0.01 | $0.6 |
| 96417 Chemotherapy Administration | Office | 54 | 11 | $55.41 | $2,992 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 46 | 12 | $0.01 | $0.62 |
By year: 2022 $248K for 8,910 services; 2023 $162K for 10,940 services; 2024 $476K for 5,459 services.
Medicare prescription drug claims, 2024
In 2024, the drug Ghassan Al-Jazayrly prescribed most often to Medicare patients was Xgeva (Denosumab), with 113 prescriptions and refills. In total Ghassan Al-Jazayrly wrote 1,453 Medicare prescriptions that cost $3.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Xgeva Denosumab | 113 | 113 | 15 | $318K |
| Opdivo Nivolumab | 88 | 88 | 12 | $631K |
| Ondansetron Hcl Ondansetron Hcl/Pf | 82 | 82 | 22 | $292 |
| Lupron Depot Leuprolide Acetate | 63 | 63 | Under 11 | $120K |
| Procrit Epoetin Alfa | 60 | 60 | 12 | $162K |
| Avastin Bevacizumab | 57 | 57 | Under 11 | $244K |
| Dexamethasone Sodium Phosphate Generic | 53 | 58 | 19 | $81.07 |
| Diphenhydramine Hcl Generic | 50 | 55 | 19 | $74.77 |
| Keytruda Pembrolizumab | 43 | 43 | Under 11 | $458K |
| Prolia Denosumab | 36 | 216 | 19 | $56K |
| Prednisone Generic | 32 | 32 | Under 11 | $72.39 |
| Famotidine Famotidine/Pf | 31 | 31 | Under 11 | $22.81 |
| Yervoy Ipilimumab | 29 | 33 | Under 11 | $442K |
| Oxaliplatin Generic | 29 | 29 | Under 11 | $2,827 |
| Cyclophosphamide Generic | 28 | 28 | Under 11 | $9,541 |
Brand drugs: 735 claims; generic drugs: 718 claims; opioid claims: 18.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Ghassan Al-Jazayrly $117 ($117 in general payments such as food, travel and fees) from 9 companies. The largest payer was E.R. Squibb & Sons, L.L.C. with $47.6.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.